The glutamate neurotransmitter system is one of the major candidate pathways for the
pathophysiology of schizophrenia, and increased understanding of the pharmacology …

Considering the lengthy history of pharmacological treatment of schizophrenia, the
development of novel antipsychotic agents targeting the glutamatergic system is relatively …

An increasing amount of evidence indicates that d-serine, a potent and selective
endogenous coagonist of the N-methyl-d-aspartate receptor (NMDAR), is efficacious in the …

D-Serine is a potent co-agonist at the NMDA glutamate receptor and has been the object of
many preclinical studies to ascertain the nature of its metabolism, its regional and cellular …

BACKGROUND: D-serine, a selective full agonist at the glycine site of N-methyl-d-aspartate
glutamate receptor, might presently be the compound of choice for counteracting the …

Highlights•NMDA receptor (NMDAR) hypofunction contributes to the etiology of
schizophrenia.•Serine racemase, a risk gene for schizophrenia, is expressed primarily in …

Clinical trials demonstrated that d-serine administration improves schizophrenia symptoms,
raising the possibility that altered levels of endogenous d-serine may contribute to the N …

D‐Serine (DSR) is an endogenous amino acid involved in glia‐synapse interactions that
has unique neurotransmitter characteristics. DSR acts as obligatory coagonist at the glycine …

Background: Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has
been implicated in the pathophysiology of schizophrenia. D-serine is a full agonist of the …

Changes in D-serine availability in the brain may contribute to the hypofunction of NMDA-
glutamate receptors in schizophrenia; however, measurements of blood levels of D-serine in …